Mr. Elms serves as a Managing Director of the Perseus-Soros BioPharmaceutical Fund (PSBF) and Managing Partner of Aisling Capital LLC. He joined PSBF in mid-2000 from the Life Sciences Investment Banking Group of Chase H&Q (formerly Hambrecht and Quist) where he was a Principal. During his five years at Hambrecht and Quist, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to Hambrecht and Quist, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin and Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms serves as a director of MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) and a number of private companies.

Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from the Kellogg School of Management at Northwestern University.

Dr. Goldstein serves as a Principal of Aisling Capital. Previously, Dr. Goldstein was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals up until its acquisition by Pfizer for $1.9 billion. While at Vicuron Pharmaceuticals, he raised over $250 million dollars in an IPO, PIPE, Follow-on, and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first US and Italian public to public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures. He also completed an internship in the Department of Medicine, at Columbia-Presbyterian Hospital. Dr. Goldstein currently serves as a director of ADMA Biologics, BioRelix, CardioKine, Cempra Pharmaceuticals, Esperion Therapeutics, and Topaz Pharmaceuticals.

Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and he received his B.S. with honors from Stanford University.

Mr. Casale has over 23 years of healthcare experience. Most recently, he was the Chief Operating Officer of Adams Respiratory Therapeutics. Mr. Casale joined Adams in 2004 as Vice President, Marketing and Business Development and was named Chief Operating Officer in 2006. Mr. Casale was a driving force behind the growth of the Adams business, which grew from $60 million to near $500 million under his leadership. He led the diversification of the Adams' portfolio of products by launching Mucinex D and DM, Mucinex for Children, Mucinex Nasal Spray, and acquiring the Delsym brand. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.

Mr. Casale began his career in 1983 at a Wall Street law firm and joined the legal division of Warner Lambert in 1986. In 1993, he was appointed Warner-Lambert's Vice President of Marketing for the company's upper respiratory and gastrointestinal (GI) consumer products and oversaw several brands, including Benadryl, Sudafed, Zantac 75 and Rolaids. Mr. Casale also served as a global vice president for Warner-Lambert's GI and skin care businesses. Following Warner-Lambert's acquisition by Pfizer Inc., he served as Vice President, Strategic Planning and Business Development for Pfizer's Consumer Healthcare Division.

Mr. Casale is also the non-executive Chairman of Topaz Pharmaceuticals and serves on the Board of Directors of NextWave Pharmaceuticals, both specialty pharmaceutical companies. He has an undergraduate and a law degree from Rutgers University.

Ms. Arnett has over 19 years experience in the marketing and management of healthcare products. Previously, she was Senior Vice President, Marketing and Advertising for Adams Respiratory Therapeutics, the makers of Mucinex and Delsym.

Ms. Arnett joined Adams in 2004 as the Director of Marketing and was a lead architect in the marketing of Mucinex and Delsym, including the development of the award winning Mr. Mucus advertising campaign. She played a key role in growing the Adams business from $60 million to nearly $500 million over the span of 4 years. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.

Prior to Adams, Ms. Arnett managed a broad spectrum of OTC and HBA businesses at Pfizer Consumer Healthcare and its predecessor Warner Lambert Consumer Healthcare including such brands as Listerine, Lubriderm, Benadryl and e.p.t. Over the course of her career, Ms. Arnett has won several marketing, advertising and PR awards. She was named one of the top 50 marketers of the year by Advertising Age in 2006 and one of the top 20 marketers of the year by OTC Perspectives in 2008. She began her career in commercial banking with Chase Manhattan Bank. Ms. Arnett received an M.B.A from Columbia University Graduate School of Business and a B.A. from Yale University.